Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1308 in advanced solid tumors
NCT05155722Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAT1308 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 1 more, sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Sep 2020; status: completed.
02
Drugs
BAT1308
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05155722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155722.